Google
TECH Stock Analysis — BIO-TECHNE CORP (Healthcare >> Biotechnology)
TECH FAQ
What is TECH's P/E ratio?
BIO-TECHNE CORP (TECH) currently trades at a P/E ratio of 88.20.
What is TECH's ROE?
BIO-TECHNE CORP reports a Return on Equity (ROE) of 5.25%.
What is TECH's dividend yield?
BIO-TECHNE CORP offers a dividend yield of 0.44%.
What is TECH's Quality Score?
Our AI rates TECH's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TECH?
Our AI Timing Score for TECH is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TECH belong to?
BIO-TECHNE CORP is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
TECH AI Analysis Summary
Our AI summary for TECH: BIO-TECHNE CORP (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 88.20, ROE of 5.25%, a dividend yield of 0.44%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 72.09
Price
0.06
(0.08%)
Day Change
|
|
|---|
TECH, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
2775
|
| Magic Formula Rank by ROE |
2775
|
| Magic Formula Rank by ROIC |
2875
|
| Price | 72.09 |
| PBV / Sector |
5.38 / 5.20
|
| Earning Per Share | 0.70 |
| PE / Sector |
88.20 / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
277.83 M
GREAT
|
| Average 1W Daily Value |
373.69 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
58% |
| Return to Investors |
|
12% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:34 |
| Symbol | TECH |
| Name | BIO-TECHNE CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 155.81 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 11,223.04 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 614 McKinley Place N.E., Minneapolis, MN, United States, 55413
Phone: 612 379 8854
Website: https://www.bio-techne.com
Employees: 3,100
Sector: Healthcare >> Biotechnology
Description: Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap